Covalon to Showcase IV Clear at AVA Scientific Meeting 2018

Covalon to Showcase IV Clear at AVA Scientific Meeting 2018

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV.V; OTCQX: CVALF), an advanced medical technologies company, today announces that it will be showcasing IV Clear at the 2018 Scientific Meeting for the Association for Vascular Access (“AVA” or the “Meeting”).

Covalon’s IV Clear™ is indicated to cover and protect vascular access devices used in a wide variety of both acute and alternate care settings. Its patented combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most commonly associated blood stream infection bacteriaⁱ and its skin-sparing silicone adhesive will not cause adhesive-related skin injury or pain during dressing changesⁱⁱ.

Covalon is also co-sponsoring a presentation on patient advocacy by Emily Levy, CEO and co-founder of Mighty Well, entitled “Empowering Vascular Access Specialists: How to Better Inform Patients of Their Options When It Comes to Their Long-Term Care”. Ms. Levy is a strong patient advocate and is passionate about advocating for the patient perspective in healthcare. Ms. Levy will be presenting on Tuesday September 17th at 11:15am, Room C161.

Covalon will be at AVA, Booth 123, at the Columbus Convention Center in Columbus, Ohio from September 15th to 17th during all exhibit hours throughout the meeting.

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit www.covalon.com.

ⁱ A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American Journal of Infection Control , Volume 43 , Issue 6 , S22
ⁱⁱ A Human Repeat Patch Test Study, DiTizio et al. http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Covalon Technologies Ltd.
Brian Pedlar, 905.568.8400 x 233
CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon

View source version on businesswire.com: https://www.businesswire.com/news/home/20180914005513/en/